64
Participants
Start Date
September 14, 2018
Primary Completion Date
February 21, 2023
Study Completion Date
February 21, 2023
AMG 427
AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
The Alfred Hospital, Melbourne
The Royal Melbourne Hospital, Parkville
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
Johns Hopkins, Baltimore
Duke University Medical Center, Durham
Northwestern University, Evanston
University of Texas MD Anderson Cancer Center, Houston
Klinikum der Universitaet Muenchen Campus Grosshadern, München
City of Hope National Medical Center, Duarte
University Health Network-Princess Margaret Cancer Centre, Toronto
Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden
National Cancer Center Hospital East, Kashiwa-shi
University of Fukui Hospital, Yoshida-gun
Seoul National University Hospital, Seoul
Severance Hospital Yonsei University Health System, Seoul
Lead Sponsor
Amgen
INDUSTRY